Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate-specific antigen in men born with bladder exstrophy

R I Silver1, A W Partin, J I Epstein

  • 1Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland 21287, USA.

Urology
|February 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance.

Prostate cancer and prostatic diseases·2017
Same author

Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, Carter HB.J Clin Oncol. 2015 Oct 20;33(30):3379-85. [Epub 2015 Aug 31]. doi: 10.1200/JCO.2015.62.5764.

Urologic oncology·2017
Same author

Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.

Prostate cancer and prostatic diseases·2017
Same author

DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-β/SMAD4 signaling.

Oncogene·2016
Same author

Implicit Theory Of Psychopathology.

Multivariate behavioral research·2016
Same author

Very-high-risk localized prostate cancer: definition and outcomes.

Prostate cancer and prostatic diseases·2013
Same journal

"Editorial Comment on "Vaginal Estrogen Prescription is Associated with Reduced Rates of Serious Adverse Outcomes in Women of All Age Groups With Recurrent Urinary Tract Infection: An Epic Cosmos Database Analysis".

Urology·2026
Same journal

The True Oral History of Buccal Mucosal Grafts for Male Urethral Stricture Repair.

Urology·2026
Same journal

Preventing Postpartum Pelvic Floor Dysfunction: Clinical Evidence and Policy Gaps in U.S. Coverage of Pelvic Floor Muscle Therapy.

Urology·2026
Same journal

Editorial Comment on "Through the Eyes of the Applicant: A Qualitative Study of the Urology Residency Match".

Urology·2026
Same journal

Editorial Comment on "A Histopathologic Assessment of Prostate Ductal Anatomy in Relation to Micro-Ultrasound".

Urology·2026
Same journal

Same-Day Discharge Following Multiport Robot-Assisted Simple Prostatectomy: A Prospective Feasibility Study of Outcomes, Costs, and Post-Discharge Healthcare Utilization.

Urology·2026
See all related articles

Men with bladder exstrophy have detectable prostate-specific antigen (PSA) levels, but its clinical utility as a tumor marker for prostate cancer in this population requires further study.

Area of Science:

  • Urology
  • Oncology
  • Developmental Biology

Background:

  • Bladder exstrophy is a rare congenital condition affecting the genitourinary system.
  • Prostate-specific antigen (PSA) is a key biomarker for prostate health and cancer detection in the general population.

Purpose of the Study:

  • To measure serum PSA levels in adult men with a history of bladder exstrophy.
  • To assess the potential clinical utility of PSA testing in this unique population.

Main Methods:

  • Serum PSA (free and total) was measured in 10 men (aged 19-45) with bladder exstrophy.
  • Immunohistochemistry for PSA and PSAP was performed on archival prostate tissue from one patient.

Main Results:

  • All participants had measurable serum PSA levels below established age-specific reference ranges.

Related Experiment Videos

  • PSA and PSAP were detected in prostate epithelial cells of the tissue sample.

    • Conclusions:

    • Men with bladder exstrophy exhibit detectable serum PSA.
    • The role of PSA as a prostate cancer tumor marker in this population is undetermined and requires further investigation.
    • Establishing specific PSA reference ranges and continued clinical monitoring for prostate abnormalities are recommended.